摘要本文检索并总结特应性皮炎（AD）长期控制的评价指标及治疗目标的研究进展，其中，特应性湿疹治疗工作组将最低随访时间定为开始治疗后最初4周、治疗期间每3个月以及停止治疗后每6个月；湿疹结局测量一致化组织推荐以特应性湿疹概述或AD控制工具作为长期控制效果的评估工具。为实现AD患者的达标治疗，2021年初来自28个国家的87人团队制定并发表了《AD的达标治疗：关于系统治疗的一系列核心决策的国际共识》：以3个月及6个月为评估节点，综合多种疾病指标以及患者总体评分，通过设定达标阈值，进而调整治疗方案。本文总结梳理AD长期控制效果评估及达标治疗相关概念和指标，希望对国内AD的临床治疗，特别是疾病的长期控制有所启发。

abstractsResearch progress in the establishment of long-term control goals and treat-to-target in the treatment of atopic dermatitis (AD) was searched and summarized in this review. The TREatment of ATopic eczema (TREAT) Registry Taskforce defined a minimum follow-up frequency of initially 4 weeks after commencing treatment, then every 3 months while on treatment and every 6 months while off treatment; the international Harmonising Outcome Measures for Eczema (HOME) group recommended that the long-term control of AD should be measured by either the Recap of Atopic Eczema (RECAP) instrument or the Atopic Dermatitis Control Tool (ADCT) . In order to achieve the treat-to-target in AD, a panel comprising 87 participants from 28 countries developed and published "Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies" in early 2021, which recommended 3 months and 6 months as two evaluation time points, and various disease outcome domains spanning symptoms, signs, quality of life plus patient global assessment as the target. By setting the time-specific outcome thresholds, the consensus provided a framework for shared decision-making on systemic treatment adjustment for AD patients. This review summarizes concepts and indicators related to the assessment of long-term control of and treat-to-target in AD, in the hope of providing some ideas for clinical management, especially the long-term control, of AD in China.